Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Phase 4
Completed
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Other: sham
- Registration Number
- NCT01025934
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Brief Summary
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- vitreous haemorrhage
- tractional retinal detachment
- active proliferative diabetic retinopathy.
Exclusion Criteria
- neovascular glaucoma
- cataract
- combined traction and rhegmatogenous RD
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 7 days Bevacizumab - 20 days Bevacizumab - sham sham -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Bevacizumab's anti-VEGF effects in vitrectomy for severe proliferative diabetic retinopathy?
How does intravitreal Bevacizumab compare to ranibizumab in adjunctive vitrectomy for severe PDR outcomes?
Which biomarkers predict response to anti-VEGF therapy in patients undergoing vitrectomy for proliferative diabetic retinopathy?
What are the known adverse events of Bevacizumab in vitrectomy for PDR and their management strategies?
What combination therapies with anti-VEGF agents are being explored for PDR treatment besides Bevacizumab?